BeiGene is developing a pipeline of oral small molecules and monoclonal antibodies to fight cancer. Get up to date with the BeiGene hematology pipeline and clinical trials.
Slide kit outlining a new therapeutic approach for previously untreated chronic lymphocytic leukemia (CLL)
Poster presented at ASH 2022 evaluating new therapeutic approaches for patients with B-cell malignancies who received prior BTKi treatment and became intolerant.
Poster presented at ASH 2022 describing the genomic analysis of patients with R/R B‑cell malignancies who were previously intolerant to certain BTKi’s.
Poster presented at ASH 2022 evaluating the use of BTKi in Japanese patients with B-cell malignancies.